sVEGFR-2 and its role in lymphangiogenesis modulation
US8846386B2 · kind B2 · utility
13Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2008 |
| Grant date | Sep 30, 2014 |
| Priority date | — |
| Expiry date | Sep 29, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed herein are nucleic acid molecules comprising a nucleotide sequence of sVEGF-2, proteins encoded by those sequences and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing expression or activity of sVEGFR-2 and methods for inhibiting graft rejection, particularly cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.